CU23774A3 - Inhibición de arni de expresión de alfa-enac - Google Patents

Inhibición de arni de expresión de alfa-enac

Info

Publication number
CU23774A3
CU23774A3 CU20090215A CU20090215A CU23774A3 CU 23774 A3 CU23774 A3 CU 23774A3 CU 20090215 A CU20090215 A CU 20090215A CU 20090215 A CU20090215 A CU 20090215A CU 23774 A3 CU23774 A3 CU 23774A3
Authority
CU
Cuba
Prior art keywords
arni
alfa
inhibition
enac expression
enac
Prior art date
Application number
CU20090215A
Other languages
English (en)
Inventor
Hans-Peter Vornlocher
Anke Geick
Henry Luke Danahay
Pamela Tan
Ema Hickman
Heeke Gino Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU23774A3 publication Critical patent/CU23774A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Abstract

La invención se refiere a composiciones y métodos para modular la expresión de alfa-ENaC, y más particularmente a la disminución de la expresión de alfa-ENaC mediante oligonucleótidos químicamente modificados.
CU20090215A 2007-06-15 2009-12-15 Inhibición de arni de expresión de alfa-enac CU23774A3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07114265 2007-08-13

Publications (1)

Publication Number Publication Date
CU23774A3 true CU23774A3 (es) 2012-02-15

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090215A CU23774A3 (es) 2007-06-15 2009-12-15 Inhibición de arni de expresión de alfa-enac

Country Status (26)

Country Link
US (12) US7718632B2 (es)
EP (7) EP2224004B1 (es)
JP (6) JP5485146B2 (es)
KR (2) KR101821081B1 (es)
CN (1) CN101778941B (es)
AR (1) AR066984A1 (es)
AU (1) AU2008263876B2 (es)
BR (1) BRPI0813680A8 (es)
CA (1) CA2690674C (es)
CL (1) CL2008001756A1 (es)
CO (1) CO6251331A2 (es)
CR (1) CR11136A (es)
CU (1) CU23774A3 (es)
EA (1) EA200901653A1 (es)
EC (1) ECSP099794A (es)
ES (6) ES2439277T3 (es)
GT (1) GT200900315A (es)
IL (1) IL202366A0 (es)
MA (1) MA31564B1 (es)
MX (1) MX2009013609A (es)
PE (1) PE20090942A1 (es)
SG (3) SG10201601846VA (es)
SV (1) SV2009003434A (es)
TN (1) TN2009000521A1 (es)
TW (3) TWI552753B (es)
WO (1) WO2008152131A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427352T1 (de) 2002-07-26 2009-04-15 Novartis Vaccines & Diagnostic Modifizierte kleine irns molekule und methoden zu deren anwendung
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
EP1796732B1 (en) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
BRPI0920933A2 (pt) * 2008-11-26 2019-09-24 Merck Sharp & Dohme molécula de ácido nucleico de dupla fita, composição farmacêutica, e, método para tratar um indivíduo humano sofrendo de uma condição
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
US8563710B2 (en) 2009-04-03 2013-10-22 Biomics Biotechnologies Co., Ltd. Modified oligonucleotide and its preparation and application
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
CA2780741C (en) * 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US8293718B2 (en) * 2009-12-18 2012-10-23 Novartis Ag Organic compositions to treat HSF1-related diseases
KR20220008383A (ko) 2010-04-23 2022-01-20 애로우헤드 파마슈티컬스 인코포레이티드 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물
US8916352B2 (en) 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
AU2012245188A1 (en) 2011-04-20 2013-12-05 Smith, Larry J Methods and compositions for modulating gene expression using components that self assemble in cells and produce RNAi activity
WO2013030778A2 (en) 2011-09-02 2013-03-07 Novartis Ag Organic compositions to treat hsf1-related diseases
HRP20220181T1 (hr) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrinski ligandi i njihova uporaba
EP3649240A4 (en) * 2017-07-06 2021-07-07 Arrowhead Pharmaceuticals, Inc. RNAI ALPHA-ENaC GENE EXPRESSION INHIBITION AGENTS AND METHODS OF USE
MX2020003554A (es) * 2017-10-31 2020-08-03 Ionis Pharmaceuticals Inc Moduladores de la expresion de enac.
SG11202002967SA (en) * 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
EP4021413A4 (en) * 2019-08-30 2023-07-05 United States Government as Represented by The Department of Veterans Affairs LIPOSOMAL TROPONOID COMBINATION FORMULATIONS
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
WO1994018987A1 (en) 1993-02-19 1994-09-01 Nippon Shinyaku Co., Ltd. Drug composition containing nucleic acid copolymer
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (de) 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
CA2283293A1 (en) * 1997-03-11 1998-09-17 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5976849A (en) 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
TR200401292T3 (tr) * 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften RNAÁgirişimineÁyolÁaçanÁküçükÁRNAÁmolekülleri
EP1399593A2 (en) 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
ATE427352T1 (de) 2002-07-26 2009-04-15 Novartis Vaccines & Diagnostic Modifizierte kleine irns molekule und methoden zu deren anwendung
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
JP2006517092A (ja) 2002-11-27 2006-07-20 アルテシアン セラピューティック，インコーポレイティド 心不全遺伝子の決定及び治療薬スクリーニング
CN1694899B (zh) 2002-11-29 2011-07-06 赢创德固赛有限公司 生产甲硫氨酸的方法
DE10305213A1 (de) * 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
EP1608763A2 (en) * 2003-03-31 2005-12-28 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
WO2006066158A2 (en) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US20070149456A1 (en) * 2005-12-13 2007-06-28 University Of Pittsburgh Epithelial sodium channel inhibiting agents and uses therefor
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
JP2010505897A (ja) 2006-10-11 2010-02-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ インフルエンザターゲット
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
EP2223693A1 (en) 2010-09-01
GT200900315A (es) 2011-10-05
JP2015145393A (ja) 2015-08-13
MA31564B1 (fr) 2010-08-02
BRPI0813680A2 (pt) 2015-01-06
KR101821081B1 (ko) 2018-01-23
US20220235361A1 (en) 2022-07-28
TW201524510A (zh) 2015-07-01
MX2009013609A (es) 2010-01-20
US11208662B2 (en) 2021-12-28
US10544418B2 (en) 2020-01-28
JP2010530369A (ja) 2010-09-09
US9476052B2 (en) 2016-10-25
JP2020094063A (ja) 2020-06-18
US7718632B2 (en) 2010-05-18
BRPI0813680B1 (pt) 2018-02-06
CR11136A (es) 2010-01-20
EP2224005A1 (en) 2010-09-01
JP7157775B2 (ja) 2022-10-20
TW201636027A (zh) 2016-10-16
TN2009000521A1 (en) 2011-03-31
JP6680728B2 (ja) 2020-04-15
EP2223693B1 (en) 2013-07-24
PE20090942A1 (es) 2009-08-05
EP2223692B1 (en) 2013-07-24
US9074212B2 (en) 2015-07-07
US8168606B2 (en) 2012-05-01
JP6193906B2 (ja) 2017-09-06
AU2008263876A1 (en) 2008-12-18
ES2432532T3 (es) 2013-12-04
US20100216972A1 (en) 2010-08-26
WO2008152131A3 (en) 2009-05-28
US20200157550A1 (en) 2020-05-21
IL202366A0 (en) 2011-08-01
ES2439277T3 (es) 2014-01-22
KR20100039335A (ko) 2010-04-15
US20220112505A1 (en) 2022-04-14
TWI444474B (zh) 2014-07-11
EP2224005B1 (en) 2013-09-11
CA2690674C (en) 2018-09-11
SG10201601846VA (en) 2016-04-28
CL2008001756A1 (es) 2009-02-20
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
CO6251331A2 (es) 2011-02-21
BRPI0813680A8 (pt) 2018-08-28
SG10201404955RA (en) 2014-10-30
ES2432157T3 (es) 2013-12-02
EP2224004B1 (en) 2013-07-24
US20160376599A1 (en) 2016-12-29
TW200911989A (en) 2009-03-16
JP5485146B2 (ja) 2014-05-07
US20180148726A1 (en) 2018-05-31
WO2008152131A2 (en) 2008-12-18
KR20160105530A (ko) 2016-09-06
EP2223695A1 (en) 2010-09-01
SV2009003434A (es) 2011-03-23
KR101653008B1 (ko) 2016-08-31
ES2432643T3 (es) 2013-12-04
ES2432158T3 (es) 2013-12-02
CA2690674A1 (en) 2008-12-18
US20100216971A1 (en) 2010-08-26
JP2014129373A (ja) 2014-07-10
AR066984A1 (es) 2009-09-23
AU2008263876B2 (en) 2012-04-12
EA200901653A1 (ru) 2010-06-30
ECSP099794A (es) 2010-01-29
JP2022188234A (ja) 2022-12-20
EP2223694A1 (en) 2010-09-01
US9914927B2 (en) 2018-03-13
EP2224004A1 (en) 2010-09-01
EP2223695B1 (en) 2013-07-24
US7943592B2 (en) 2011-05-17
US20090156529A1 (en) 2009-06-18
US20150284726A1 (en) 2015-10-08
ES2432644T3 (es) 2013-12-04
SG169988A1 (en) 2011-04-29
JP5719047B2 (ja) 2015-05-13
US20100210513A1 (en) 2010-08-19
EP2223694B1 (en) 2013-07-24
EP2223692A1 (en) 2010-09-01
EP2171059A2 (en) 2010-04-07
JP2017222704A (ja) 2017-12-21
US7939508B2 (en) 2011-05-10
TWI629063B (zh) 2018-07-11
US20100190714A1 (en) 2010-07-29
US8119612B2 (en) 2012-02-21
TWI552753B (zh) 2016-10-11
US20100210514A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
UA107791C2 (en) Pesticidal compositions
EA200801959A1 (ru) Высокоразветвленный полипропилен
RS54217B1 (en) SOME TRIAZOLOPIRAZINS, THEIR COMPOSITIONS AND THE METHODS OF USING THEM
CL2008002775A1 (es) Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CL2012000315A1 (es) Compuestos derivados de heterociclos; y proceso de aplicacion de dichos compuestos.
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CL2008003395A1 (es) Compuestos derivados de 1h-2-tia-1,5,8-triaza-naftaleno 2,2-dioxido; compuestos intermediarios; metodo para controlar plantas; y composicion herbicida que comprende a dichos compuestos.
UY32469A (es) Composiciones y metodos para modular la senda de señalizacion de wnt
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
BRPI0814745A2 (pt) Composição de produto.
NO20082413L (no) Mikrobiocidal sammensetning
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
FI20065388A0 (fi) Betuliiniperäiset yhdisteet antimikrobisina aineina
UY31688A1 (es) Plaguicidas
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
CR10213A (es) Moduladores de la proteína quinasa aurora
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2008000585A1 (es) Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.
RS54158B1 (en) AMILOID BINDING AGENTS
UA106880C2 (uk) Нові гербіциди
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)